Evidence map›Paper›PMID 34657503›Full record

ArticleTechnology in cancer research & treatment

Challenges in Advanced Lung Cancer Diagnosis During the COVID-19 Pandemic.

Chunhua Xu, Li Li, Wei Wang

Open access · goldAbstract read
In one paragraph

Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Chunhua Xu206608Nanjing Chest Hospital, Nanjing, China.ORCID 0000-0001-8728-2183
Li Li206608Nanjing Chest Hospital, Nanjing, China.
Wei Wang206608Nanjing Chest Hospital, Nanjing, China.
Nanjing Brain Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A pandemic of coronavirus diseases 2019 (COVID-19) outbreak is a major public health emergency that has spread in the fastest speed, and caused the most extensive infection world widely. Transbronchial biopsy (TBB) and computed tomography guided percutaneous needle biopsy (CTPNB) is the most common and significant method for the diagnosis of lung cancer. During the COVID-19 pandemic, the indications of TBB and CTPNB must be managed strictly. Therefore, it is extremely indispensable to perform meticulous and individualized management for lung cancer patients to protect the patients from COVID-19.

Indexed as

BiopsyBronchiBronchoscopyCOVID-19Diagnosis, DifferentialDisease SusceptibilityHumansImage-Guided BiopsyLungLung NeoplasmsMedical OncologyPostoperative PeriodPrognosisSARS-CoV-2TelemedicineTomography, X-Ray ComputedCoronavirus disease 2019 (COVID-19)diagnosislung cancerpercutaneous needle biopsytransbronchial biopsy

Identifiers

PMID34657503
PMCPMC8524682
OpenAlexW3205785760

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.